Floatz logo

Docetaxel

Non-Small-Cell Lung Adenocarcinoma

BeyondSpring Pharmaceuticals Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

67 Active assets in the Non-Small-Cell Lung Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Guangdong Association of Clinical Trials
Phase 3BBB
Cyclophosphamide
Anusha Kalbasi
Phase 2BBB
Nivolumab
Emory University
Phase 3BB
ETOPOSIDE
Guangdong Association of Clinical Trials
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →